Patient characteristics and treatment outcomes of 104 AML patients enrolled in this study
| . | All cohort . | Post-HCT VAF . | P . | |
|---|---|---|---|---|
| <0.2% . | ≥0.2% . | |||
| N = 104 . | N = 88 . | N = 16 . | ||
| No. (%)* . | ||||
| Age at HCT, median (range), y | 42 (15-63) | 42 (15-63) | 42 (18-62) | .974 |
| Male sex | 51 (49) | 44 (50) | 7 (44) | .787 |
| Cytogenetic risk at diagnosis† | ||||
| Favorable | 16 (15) | 14 (16) | 2 (13) | .761 |
| Intermediate | 74 (71) | 61 (69) | 13 (81) | |
| Adverse | 14 (14) | 13 (15) | 1 (6) | |
| ELN risk group‡ | ||||
| Favorable | 31 (30) | 26 (29) | 5 (31) | .737 |
| Intermediate | 47 (45) | 41 (47) | 6 (38) | |
| Adverse | 26 (25) | 21 (24) | 5 (31) | |
| Mutations at diagnosis | ||||
| FLT3-ITD | 31 (30) | 22 (25) | 9 (56) | .011 |
| DNMT3A | 26 (25) | 18 (20) | 8 (50) | .024 |
| NPM1 | 23 (22) | 17 (19) | 6 (38) | .186 |
| IDH2 | 15 (14) | 12 (14) | 3 (19) | .698 |
| Disease status prior to HCT | ||||
| CR1 | 104 (100) | 88 (100) | 16 (100) | 1.00 |
| Stem cell source | ||||
| BM | 7 (7) | 7 (8) | 0 (0) | .592 |
| Peripheral blood | 97 (93) | 81 (92) | 16 (100) | |
| Donor | ||||
| Related | 68 (65) | 59 (67) | 9 (56) | .407 |
| Unrelated | 36 (35) | 29 (33) | 7 (44) | |
| HLA disparity | ||||
| Full matched | 86 (83) | 75 (85) | 11 (69) | .147 |
| Mismatched | 18 (17) | 13 (15) | 5 (31) | |
| Conditioning intensity | ||||
| Myeloablative conditioning | 85 (82) | 75 (85) | 10 (63) | .071 |
| RIC | 19 (18) | 13 (15) | 6 (37) | |
| T-cell depletion | 41 (39) | 33 (38) | 8 (50) | .409 |
| GVHD prophylaxis | ||||
| Cyclosporine ± MTX | 62 (60) | 54 (61) | 8 (50) | .418 |
| Tacrolimus ± MTX | 42 (40) | 34 (39) | 8 (50) | |
| Acute GVHD | 28 (27) | 24 (27) | 4 (25) | .999 |
| Chronic GVHD | 59 (57) | 53 (60) | 6 (38) | .107 |
| Relapse | 23 (22) | 14 (16) | 9 (56) | .001 |
| Death | 41 (39) | 31 (35) | 10 (63) | .053 |
| . | All cohort . | Post-HCT VAF . | P . | |
|---|---|---|---|---|
| <0.2% . | ≥0.2% . | |||
| N = 104 . | N = 88 . | N = 16 . | ||
| No. (%)* . | ||||
| Age at HCT, median (range), y | 42 (15-63) | 42 (15-63) | 42 (18-62) | .974 |
| Male sex | 51 (49) | 44 (50) | 7 (44) | .787 |
| Cytogenetic risk at diagnosis† | ||||
| Favorable | 16 (15) | 14 (16) | 2 (13) | .761 |
| Intermediate | 74 (71) | 61 (69) | 13 (81) | |
| Adverse | 14 (14) | 13 (15) | 1 (6) | |
| ELN risk group‡ | ||||
| Favorable | 31 (30) | 26 (29) | 5 (31) | .737 |
| Intermediate | 47 (45) | 41 (47) | 6 (38) | |
| Adverse | 26 (25) | 21 (24) | 5 (31) | |
| Mutations at diagnosis | ||||
| FLT3-ITD | 31 (30) | 22 (25) | 9 (56) | .011 |
| DNMT3A | 26 (25) | 18 (20) | 8 (50) | .024 |
| NPM1 | 23 (22) | 17 (19) | 6 (38) | .186 |
| IDH2 | 15 (14) | 12 (14) | 3 (19) | .698 |
| Disease status prior to HCT | ||||
| CR1 | 104 (100) | 88 (100) | 16 (100) | 1.00 |
| Stem cell source | ||||
| BM | 7 (7) | 7 (8) | 0 (0) | .592 |
| Peripheral blood | 97 (93) | 81 (92) | 16 (100) | |
| Donor | ||||
| Related | 68 (65) | 59 (67) | 9 (56) | .407 |
| Unrelated | 36 (35) | 29 (33) | 7 (44) | |
| HLA disparity | ||||
| Full matched | 86 (83) | 75 (85) | 11 (69) | .147 |
| Mismatched | 18 (17) | 13 (15) | 5 (31) | |
| Conditioning intensity | ||||
| Myeloablative conditioning | 85 (82) | 75 (85) | 10 (63) | .071 |
| RIC | 19 (18) | 13 (15) | 6 (37) | |
| T-cell depletion | 41 (39) | 33 (38) | 8 (50) | .409 |
| GVHD prophylaxis | ||||
| Cyclosporine ± MTX | 62 (60) | 54 (61) | 8 (50) | .418 |
| Tacrolimus ± MTX | 42 (40) | 34 (39) | 8 (50) | |
| Acute GVHD | 28 (27) | 24 (27) | 4 (25) | .999 |
| Chronic GVHD | 59 (57) | 53 (60) | 6 (38) | .107 |
| Relapse | 23 (22) | 14 (16) | 9 (56) | .001 |
| Death | 41 (39) | 31 (35) | 10 (63) | .053 |
GVHD, graft-versus-host disease; MTX, methotrexate; RIC, reduced-intensity conditioning.
No. (%) unless otherwise specified in the row heading.
Cytogenetic risk group is defined by revised Medical Research Council criteria.3
ELN risk group is defined by 2017 ELN recommendations from an international expert panel.40